Clinical application of ultrasound-guided percutaneous microwave ablation in the treatment of T1aN0M0 stage renal carcinoma.
Evaluation of clinical application of ultrasound-guided percutaneous microwave ablation treatment for T1a renal carcinoma. Analysis of the clinical data from 31 patients with T1aN0M0 stage renal carcinoma who underwent ultrasound-guided percutaneous microwave ablation in the Department of Ultrasound of China-Japan Union Hospital of Jilin University between March 2010 and June 2014. All of the 31 patients were treated with ablation only once: 96.8% (30/31) of patients had no local recurrence or distant metastasis after ablation. One (3.2%) patient had local tumor recurrence 6 months after surgery and underwent a second microwave ablation. According to the results of 2 years of follow-up re-examinations, no further recurrence or distant metastasis was found. Moreover, 90.3% (28/31) of the patients had no complications with normal ranges of preoperative and postoperative serum creatinine and urea nitrogen levels. Complications were found in 9.7% (3/31) of the patients: one case of transient hematuria, one case of perirenal hematoma, and one case of cholecystitis; the symptoms were resolved with symptomatic treatment. Ultrasound-guided percutaneous microwave ablation is a safe and effective micro-invasive therapy for T1a renal cancer patients.